Journal of Neuroinflammation · 2010 · 40 citations · 47 references
Life SciencesNeurobiologyNeuroscienceGlial BiologyNeurodegenerationNeuroimmunologyCell DeathDemyelinating DiseasesDemyelinating DisordersMultiple SclerosisNeuroinflammationOligodendrocyte BiologyCyclooxygenase InhibitorsCyclooxygenase PathwaysCyclooxygenase-2 PathwayExcitotoxic Cell DeathExperimental Autoimmune EncephalomyelitisMultiple Sclerosis ModelsTransgenic MiceTransgenic Mouse Models
BACKGROUND: We previously found that cyclooxygenase 2 (COX-2) was expressed in dying oligodendrocytes at the onset of demyelination in the Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) model of multiple sclerosis (MS) (Carlson et al. J.Neuroimmunology 2006, 149:40). This suggests that COX-2 may contribute to death of oligodendrocytes. OBJECTIVE: The goal of this study was to examine whether COX-2 contributes to excitotoxic death of oligodendrocytes and potentially contributes to demyelination. METHODS: The potential link between COX-2 and oligodendrocyte death was approached using histopathology of MS lesions to examine whether COX-2 was expressed in dying oligodendrocytes. COX-2 inhibitors were examined for their ability to limit demyelination in the TMEV-IDD model of MS and to limit excitotoxic death of oligodendrocytes in vitro. Genetic manipulation of COX-2 expression was used to determine whether COX-2 contributes to excitotoxic death of oligodendrocytes. A transgenic mouse line was generated that overexpressed COX-2 in oligodendrocytes. Oligodendrocyte cultures derived from these transgenic mice were used to examine whether increased expression of COX-2 enhanced the vulnerability of oligodendrocytes to excitotoxic death. Oligodendrocytes derived from COX-2 knockout mice were evaluated to determine if decreased COX-2 expression promotes a greater resistance to excitotoxic death. RESULTS: COX-2 was expressed in dying oligodendrocytes in MS lesions. COX-2 inhibitors limited demyelination in the TMEV-IDD model of MS and protected oligodendrocytes against excitotoxic death in vitro. COX-2 expression was increased in wild-type oligodendrocytes following treatment with Kainic acid (KA). Overexpression of COX-2 in oligodendrocytes increased the sensitivity of oligodendrocytes to KA-induced excitotoxic death eight-fold compared to wild-type. Conversely, oligodendrocytes prepared from COX-2 knockout mice showed a significant decrease in sensitivity to KA induced death. CONCLUSIONS: COX-2 expression was associated with dying oligodendrocytes in MS lesions and appeared to increase excitotoxic death of oligodendrocytes in culture. An understanding of how COX-2 expression influences oligodendrocyte death leading to demyelination may have important ramifications for future treatments for MS.
47
Coxibs and Cardiovascular Disease
Garret A. FitzGerald · New England Journal of Medicine · 2004 · 896 citations
Glutamate excitotoxicity in a model of multiple sclerosis
David Pitt, Peter Werner, Cedric S. Raine · Nature Medicine · 2000 · 849 citations
Failing the Public Health — Rofecoxib, Merck, and the FDA
Eric J. Topol · New England Journal of Medicine · 2004 · 598 citations · Full text